Exploring Apixaban Pharmacokinetics, Pharmacodynamics, and Safety in Hemodiafiltration Patients

Kidney Int Rep. 2024 Jun 27;9(9):2798-2802. doi: 10.1016/j.ekir.2024.06.030. eCollection 2024 Sep.

¹ Clinical Research Support Unit, Clinical Pharmacology Department, Hospital Universitari Bellvitge, L'Hospitalet del Llobregat, Spain.
² Thrombosis and Haemostasis Unit, Hospital Universitari Bellvitge, L'Hospitalet de Llobregat, Spain.
³ Department of Nephrology, Hospital Universitari de Bellvitge, Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
⁴ Experimental Nephrology and Transplantation Laboratory, Nephrology and Renal Transplantation Group, Infectious Disease and Transplantation Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
⁵ Biostatistics Unit, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain.
⁶ Clinical Laboratory Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.

No abstract available

Keywords: apixaban; dialysis; hemodiafiltration; pharmacodynamics; pharmacokinetics.